Alliance acquires global existing rights to Novartis’ obstetric drug
Alliance Pharma has acquired all existing rights to Novartis’ Syntometrine for US $11.5 million.
Syntometrine (synthetic oxytocin/ergometrine maleate) is an obstetric drug used in the final stage of labour. Novartis has sold Syntometrine in a number of countries worldwide, including Australia, New Zealand and South Africa. Between March 2012 and March 2013, the total sales of Syntometrine by the Novartis Group were US $3.2 million.
However Alliance Pharma, an England-based speciality pharma company, already owned the UK rights to this drug.
John Dawson, Alliance Pharma’s Chief Executive.
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.